750,000 Shares in Avanos Medical, Inc. $AVNS Acquired by Pentwater Capital Management LP

Pentwater Capital Management LP purchased a new position in Avanos Medical, Inc. (NYSE:AVNS) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 750,000 shares of the company’s stock, valued at approximately $18,660,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. EverSource Wealth Advisors LLC raised its position in Avanos Medical by 132.6% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,496 shares of the company’s stock valued at $28,000 after buying an additional 1,423 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in Avanos Medical by 969.3% during the second quarter. Russell Investments Group Ltd. now owns 2,545 shares of the company’s stock worth $31,000 after buying an additional 2,307 shares during the last quarter. Wexford Capital LP acquired a new position in shares of Avanos Medical during the 3rd quarter worth about $70,000. Longfellow Investment Management Co. LLC bought a new stake in Avanos Medical in the second quarter valued at approximately $75,000. Finally, Tower Research Capital LLC TRC boosted its stake in shares of Avanos Medical by 433.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,257 shares of the company’s stock worth $77,000 after acquiring an additional 5,083 shares during the period. 95.17% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts recently commented on AVNS shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Avanos Medical in a report on Monday, July 20th. Zacks Research upgraded Avanos Medical from a “strong sell” rating to a “hold” rating in a research note on Friday, June 5th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Reduce”.

Avanos Medical Price Performance

NYSE:AVNS opened at $24.99 on Thursday. Avanos Medical, Inc. has a one year low of $9.30 and a one year high of $25.49. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.48 and a quick ratio of 1.40. The company has a market cap of $1.17 billion, a PE ratio of -15.52 and a beta of 1.57. The firm’s 50 day simple moving average is $24.96 and its 200 day simple moving average is $21.30.

Avanos Medical Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.